Molecule
Sacrosidase is a sucrose-specific enzyme indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older. It is available as oral solution. MedsAcross supplies Sacrosidase for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.
Source: US FDA prescribing information
Important Administration Information Administer Sucraid with each meal or snack. Mix Sucraid with cold or room temperature water, milk or infant formula prior to administration. Administration of Sucraid in liquids other than water, milk, or infant formula has not been studied and is not recommended. Do not mix or consume Sucraid with fruit juice. Do not warm or heat the water, milk, or infant formula before or after addition of Sucraid. Administer half of the dose at the beginning of the meal or snack and the other half of the dose during the meal or snack. Recommended Dosage The recommended dosage is: Patients weighing 15 kg and less: 8,500 International Units (1 mL) administered orally with each meal or snack. Patients weighing more than 15 kg: 17,000 International Units (2 mL) administered orally with each meal or snack.
Source: US FDA prescribing information
Sucraid is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain.
Source: US FDA prescribing information
Severe Hypersensitivity Reactions Severe hypersensitivity reactions, including wheezing, rash, and pruritis, have been reported with administration of Sucraid. Sucraid contains papain, which is associated with hypersensitivity reactions. A pediatric patient in the clinical trials experienced a hypersensitivity reaction of severe wheezing that required hospitalization. Postmarketing cases of cutaneous hypersensitivity reactions have also been reported. Instruct patients or caregivers to stop Sucraid and seek medical attention if symptoms suggestive of a hypersensitivity reaction occur. Sucraid is contraindicated in patients who have had a known hypersensitivity reaction.
Source: US FDA prescribing information
The following adverse reactions associated with the use of sacrosidase were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. In clinical studies of up to 54 months duration, a total of 52 patients were treated with Sucraid. The reported adverse reactions (number of patients) were as follows: abdominal pain, vomiting, nausea, diarrhea, constipation, insomnia, headache, nervousness, and dehydration. Hypersensitivity reactions (wheezing, rash, and pruritis) have been reported.
Source: US FDA prescribing information
Fruit Juice The acidity in fruit juice may reduce the enzyme activity in Sucraid. Administration of Sucraid with liquids other than water, milk, or infant formula has not been studied and is not recommended.
Source: US FDA prescribing information
Store under refrigeration at 2°C to 8°C (36°F to 46°F). NDC# 67871-111-07 (150 x 2 mL single-use containers) Store under refrigeration, 2°C to 8°C (36°F to 46°F). Single-use container can be removed from refrigeration and stored at 15°C to 25°C (59°F to 77°F) for up to 3 days (72 hours). Protect from heat and light. 2 mL Single-Use Container Sucraid (sacrosidase) Oral Solution is available in 2 mL, single-use containers that are packaged into a foil pouch. Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Sacrosidase, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Sucraid 8500 IU/mL oral solutionOral Cold chain | QOL Medical | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 9 April 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Sacrosidase and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Sacrosidase, including Sucraid.
Yes. The US FDA first approved Sacrosidase on 9 April 1998, according to Drugs@FDA.
At least one listed presentation of Sacrosidase must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Sacrosidase is classified under ATC code A16AB06 (Sacrosidase).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.